|
시장보고서
상품코드
2039009
지역사회 획득성 세균성 폐렴(CABP) 치료제 시장 : 약물 종류별, 제형별, 투여 경로별, 유통 채널별, 지역별Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, By Dose Form, By Route of Administration, By Distribution Channel, By Geography |
||||||
지역사회 획득성 세균성 폐렴(CABP) 치료제 시장은 2026년에 19억 2,680만 달러로 추정되며, 2033년까지 32억 760만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.7%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 19억 2,680만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 7.70% | 2033년 시장 규모 예측: | 32억 760만 달러 |
지역사회 획득성 세균성 폐렴(CABP)은 패혈증을 유발하는 다양한 감염성 질환 중 가장 흔한 급성 호흡기질환입니다. 미생물학적으로는 세균이 폐렴의 일반적인 원인균이며, 전 세계적으로 가장 많은 것은 폐렴구균(Streptococcus pneumoniae)입니다. CABP는 특히 노년층에서 질병과 입원의 가장 흔한 감염 원인으로 꼽힙니다. 예를 들어, 미국 국립생물공학정보센터(NCBI)에 따르면, 2020년 3월 기준 미국 내 연간 폐렴(CAP) 발생 건수는 500만 건을 넘어섰다고 합니다.
시장 역학
주요 기업들의 무기력한 전략으로 인해 세계 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장에서 각 기업의 시장 점유율이 강화되고 있습니다. 예를 들어, 2017년 Laboratoire RIVA Group의 계열사인 Avir Pharma Inc. Pharmaceutica Ltd.와 캐나다 내 판매 및 라이선스 계약을 체결했습니다. Avir는 캐나다에서 이부코나졸의 판매 허가를 신청할 예정입니다. 'Zevtera'는 이미 캐나다 보건부로부터 병원 내 폐렴(HAP) 및 지역사회 폐렴(CAP) 성인 환자 치료제로 승인을 받았으며, 회사는 Basilea사로부터 제품을 구매하여 캐나다 내에서 판매할 예정입니다.
그러나 약제 내성균의 출현이 시장 성장을 저해하고 있습니다. 예를 들어, 2019년 11월 미국 국립생물공학정보센터(NCBI)에 발표된 논문에 따르면, 폐렴구균성 폐렴에서 세균이 베타락탐계 항균제에 대한 감수성을 유지하더라도 베타락탐계 항균제 단독 요법은 최적의 치료법이 아닐 수 있다고 합니다. 따라서 항균제 내성은 전 세계 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장을 억제할 것으로 예상됩니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 저해요인, 기회, 신약 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장의 주요 기업 프로파일을 작성했습니다. 기업 개요, 재무 실적, 제품 포트폴리오, 시장 입지, 유통 전략, 주요 발전, 전략 및 미래 계획입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 신약 출시, 약물군 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- '세계 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장' 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장 : 약물 종류별, 2021-2033년
제5장 세계의 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장 : 제형별, 2021-2033년
제6장 세계의 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장 : 투여 경로별, 2021-2033년
제7장 세계의 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장 : 유통 채널별, 2021-2033년
제8장 세계의 지역사회 획득성 세균성 폐렴(CABP) 치료제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSM 26.06.04Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market is estimated to be valued at USD 1,926.8 Mn in 2026 and is expected to reach USD 3,207.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,926.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.70% | 2033 Value Projection: | USD 3,207.6 Mn |
Community-acquired bacterial pneumonia (CABP) is most common acute respiratory illnesses among various infections triggering sepsis. Microbiologically, bacteria are common agents causing pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. CABP is the most common infectious causes of illness and hospitalization, especially in the geriatric population. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year.
Market Dynamics
Inorganic strategies amongst key players are strengthening the companies' market share in global community-acquired bacterial pneumonia (CABP) treatment drugs market. For instance, in 2017, Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. for its antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole). Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP) and for the treatment of community-acquired pneumonia (CAP) and will be purchasing product from Basilea and will commercialize in Canada.
However, antibiotic resistance in drugs is hampering the market growth. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to the beta-lactam. Therefore, antibiotic resistance are expected to restrain the global community-acquired bacterial pneumonia (CABP) treatment drugs market.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global community-acquired bacterial pneumonia (CABP) treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global community-acquired bacterial pneumonia (CABP) treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global community-acquired bacterial pneumonia (CABP) treatment drugs market.
Market Segmentation
- By Drug Class (Revenue, USD Mn, 2021-2033)
- Pleuromutilin Antibiotic
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
- Others
- By Dose Form (Revenue, USD Mn, 2021-2033)
- Solution
- Tablet
- By Route of Administration (Revenue, USD Mn, 2021-2033)
- Oral
- Intravenous
- By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region: (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Nabriva Therapeutics
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Allergan plc
- Bayer AG
- Lupin Pharmaceuticals, Inc.
- Mylan N.V.
- Sanofi S.A.
- Pfizer Inc.
- Dainippon Sumitomo Pharma
- Takeda Pharmaceutical Company Limited
- Basilea Pharmaceutica International AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Dose Form
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- Regulatory Scenario
- New Product Launches
- Collaborations and Agreements
- Market Trends
4. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pleuromutilin Antibiotic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Glycylcycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Oxazolidinone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Ketolide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022 - 2033
- North America
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (US$ Mn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Nabriva Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paratek Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Melinta Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Allergan plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lupin Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dainippon Sumitomo Pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Basilea Pharmaceutica International AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Nabriva Therapeutics
10. Section
- References
- Research Methodology
- About us and Sales Contact
